Management of non-small-cell lung cancer: recent developments
Martin Reck, David Felix Heigener, Tony S.K. Mok et al. · The Lancet · 2013
Cited by 714 works. doi:10.1016/s0140-6736(13)61502-0
Authors
References
- Global cancer statistics
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER